discontinuation of glucagon-like peptide-1 receptor agonists cessation - GLP-1agonists is higher in individuals with overweight and obesity Understanding the Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists

GLP-1agonists The discontinuation of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is a critical issue with significant clinical, policy, and equity implications. These medications, which mimic the action of the naturally occurring glucagon-like peptide-1 (GLP) hormone, have demonstrated remarkable efficacy in managing type 2 diabetes and promoting weight loss. However, a substantial percentage of patients discontinue these therapies, often within the first year of treatment, leading to a potential reversal of benefits and a weight gain after withdrawal or discontinuation.

Prevalence of Discontinuation:

Real-world data consistently reveal high discontinuation rates for GLP-1 RAs. Studies indicate that anywhere from 50% to 75% of patients stop treatment within a year, with some reporting one-year discontinuation rates as high as 74%. Specific figures highlight this trend: 26.2% at three months, 30.8% at six months, and 36Many Patients Quit Taking GLP-1 Drugs: Understanding ....5% at 12 months.2025年6月9日—GLP-1RAcessationis associated with a predictable and decelerating pattern of weight regain, which appears to plateau below pre-treatment levels. For individuals with type 2 diabetes, adherence can be a challenge, with one study noting that 70Discontinuation of Glucagon-Like Peptide-1 Receptor ....1% discontinued therapy by 24 months. Notably, the discontinuation of GLP-1RA treatment leads to weight regain, a phenomenon observed regardless of lifestyle interventions.Discontinuation of Glucagon-Like Peptide-1 Receptor ... This is particularly pronounced in individuals with overweight and obesity who do not have type 2 diabetes, where discontinuation rates are higher作者：SS Khan·2025·被引用次数：34—Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists. / Khan, Sadiya S.; Ndumele, Chiadi E.; Kazi, Dhruv S. In: JAMA, Vol. 333, No. 2, ....

Factors Influencing Discontinuation:

While the exact reasons for discontinuation vary, several factors contributeTrajectory of weight regain after cessation of GLP-1 .... The cessation of GLP-1 RA therapy often leads to a predictable, though decelerating, pattern of weight regain, which may eventually plateau below pre-treatment levels. This weight gain after GLP-1 discontinuation is a primary concern for many patientsWHO issues global guideline on the use of GLP-1 .... Furthermore, the loss of other benefits, such as improved glycemic control and reduced cardiovascular risk, can also influence a patient's decision to stop treatment. The availability of newer glucagon-like peptide-1 receptor agonists and their efficacy in obesity and diabetes management continues to be a focus of research.作者：SS Khan·2025·被引用次数：34—Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists. / Khan, Sadiya S.; Ndumele, Chiadi E.; Kazi, Dhruv S. In: JAMA, Vol. 333, No. 2, ...

Clinical and Policy Considerations:

The implications of discontinuation extend beyond individual patient outcomesIndividuals are likely to regain weight after discontinuing GLP1 RA therapy. The off-treatment follow-up periods in 3 randomized trials ranged from 3 months to .... From a policy perspective, understanding GLP-1 RA discontinuation is crucial for optimizing treatment guidelines and ensuring equitable access3天前—Questions persist around sustained weight loss, cardiometabolic outcomes, anddiscontinuationeffects, all of which require longitudinal, real- .... The FDA's concerns with unapproved GLP-1 drugs used for weight loss underscore the importance of appropriate prescribing and patient selection. The World Health Organization (WHO) issues global guideline on the use of GLP-1 receptor agonists, emphasizing their role in blood sugar control, weight loss, and reducing the risk of heart and kidney disease.

Reinitiation and Future Directions:

The concept of reinitiation of GLP-1 receptor agonists is also being exploredIs weight loss sustained after discontinuation of glucagon-like .... Discontinuation is the first date a patient is 60 days or more without any GLP-1 RA medication on hand, and understanding the timeline and effectiveness of restarting therapy is an area of ongoing research. While the benefits of GLP-1 agonists in managing chronic conditions are undeniable, addressing the challenges associated with discontinuation is paramount. This includes exploring strategies to improve adherence, manage weight regain post-cessation, and ensure that patients can sustain the health gains achieved with these powerful medicationsReal-World Adherence and Discontinuation of Glucagon .... Research into novel agonist compounds, such as retatrutide, which targets glucagon receptors alongside like peptide 1 and glucose-dependent insulinotropic polypeptide receptors, offers potential future avenues for treatment.WHO issues global guideline on the use of GLP-1 ...

The landscape of glucagon-like peptide-1 receptor agonists for obesity and diabetes is rapidly evolving.Metabolic rebound after GLP-1 receptor agonist ... Continued research into adherence, long-term outcomes, and the management of discontinuation effects is essential to maximize the therapeutic potential of this important drug class. The focus remains on understanding the full trajectory of weight regain after cessation of GLP-1 agonist therapy and developing strategies to mitigate these effects.